Shenzhen Chipscreen Biosciences grants license to GNT Biotech for new cancer molecule
Shenzhen Chipscreen Biosciences has provided exclusive license to GNT Biotech and Medicals (GNTbm) to develop and commercialize Chidamide, an oral, selective histone deacetylase (HDAC) inhibitor, in Taiwan.
Chipscreen Biosciences has conducted Phase II trials of Chidamide in peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL) patients in China, which showed clinical efficacy.
Currently, Chidamide is undergoing Phase II trial in non-small cell lung cancer (NSCLC) patients together with first line PC therapeutic treatment.
As part of the deal, GNTbm will initially develop and commercialize Chidamide in PTCL, NSCLC and also retain the rights to develop and commercialize the inhibitor in other oncology indications in the country.
Chidamide is currently being evaluated in several clinical trials as a single agent or in combination with chemotherapeutic agents for the treatment of many hematological and solid cancers.
According to the company, the inhibitor's anticancer effects are considered to be mediated through epigenetic modulation via multiple mechanisms of action.